MarinaF.B.CaskeyMD

Physician

Overview of Dr. Caskey

Dr. Marina Caskey is an infectious disease specialist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, New York-Presbyterian Hospital, Mount Sinai Morningside, and The Mount Sinai Hospital. She received her medical degree from Other and has been in practice 19 years. She is one of 89 doctors at Mount Sinai Morningside and one of 141 doctors at The Mount Sinai Hospital who specialize in Infectious Disease. She has more than 70 publications and over 500 citings.

Office
525 E 68th St
Room A421
New York, NY 10021
Book by Phone+1(928) 440-9085

Fax+1 212-746-8675

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Infectious Disease, 2003 - 2006
Icahn School of Medicine at Mount Sinai/Morningside/WestResidency, Internal Medicine, 2000 - 2003
OtherClass of 1998

Certifications & Licensure

NY State Medical License 2003 - 2025

Clinical Trials

Study to Evaluate the Safety and Immunogenicity of Poly ICLC (Hiltonol) in Healthy Volunteers Start of enrollment: 2009 Nov 01
Completed
Phase 1
Polyinosinic-Polycytidylic Acid-poly-L-lysine Carboxymethylcellulose (Poly-ICLC) in Healthy Volunteers Start of enrollment: 2011 Jun 01
Completed
Phase 1
A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117 Start of enrollment: 2014 Jan 01
Completed
Phase 1
Romidepsin Plus 3BNC117 Phase 2a Study Start of enrollment: 2017 Jan 06
Completed
Phase 2
3BNC117 and 10-1074 in ART-treated Individuals Start of enrollment: 2018 Jun 05
Completed
Phase 1
A Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted in Healthy, HIV-uninfected Adults Start of enrollment: 2020 Aug 01
Active, not recruiting
Phase 1
3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803) Start of enrollment: 2022 Dec 07
Recruiting
Phase 1
Roles: Principal Investigator, Contact
A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral Therapy Start of enrollment: 2023 Jul 26
Recruiting
Phase 1
Roles: Contact
HepB mAb19 in Individuals With Chronic Hepatitis B Infection Start of enrollment: 2023 Aug 07
Recruiting
Phase 1
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Potential for broadly neutralising antibodies as PrEP.
Sarah Fidler, Marina Caskey
The Lancet. HIV. 2024-12-09
Evaluation and real-world experience of a neutralization susceptibility screening assay for broadly neutralizing anti-HIV-1 antibodies.
Marie Høst Pahus, Yu Zheng, Maxine Olefsky, Jesper Damsgaard Gunst, Pablo Tebas
The Journal of Infectious Diseases. 2024-10-23
The impact of analytical treatment interruptions and trial interventions on time to viral re-suppression in people living with HIV restarting ART in cure-related clini...
Ming Jie Lee, Miles Eason, Antonella Castagna, Galli Laura, Marie-Angelique De Scheerder
Journal of the International AIDS Society. 2024-08-01

Journal Articles

Relationship Between Intact HIV-1 Proviruses in Circulating CD4+ T Cells and Rebound Viruses Emerging During Treatment Interruption
Michel C Nussenzweig, Thiago Y Oliveira, Marina Caskey, Proceedings of the National Academy of Sciences
Combination Therapy with Anti-HIV-1 Antibodies Maintains Viral Suppression
Michael S Seaman, Katrina Millard, Marina Caskey, Michel C Nussenzweig, Roy M Gulick, Thiago Y Oliveira, Nature
Safety and Antiviral Activity of Combination HIV-1 Broadly Neutralizing Antibodies in Viremic Individuals
Roy M Gulick, Thiago Y Oliveira, Marina Caskey, Michel C Nussenzweig, Michael S Seaman, Katrina Millard, Nature

Press Mentions

How Close Are We to a Cure for HIV?July 6th, 2019
New Therapy May Control HIV Without Daily PillsOctober 26th, 2018
HIV Cure May Lie in Novel Immunotherapy TreatmentSeptember 28th, 2018
Join now to see all